Markets & Stocks
Stay informed about the latest developments and trends in the cannabis stock market with Business of Cannabis. Discover new investment opportunities, market analysis, and more in our stocks category.
Markets & Stocks · page 5
- CBD Market
CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited
US Medicare patients have now been given access to cannabidiol (CBD) products through a landmark federal pilot scheme, helping boost cannabis stocks.
- Public Markets
US Cannabis Companies Could Finally Get Access to NASDAQ and Financial Services Under New Bill
Bipartisan lawmakers have reintroduced a bill to the House of Representatives that would provide a pathway for cannabis businesses to list on the US stock exchange, accessing the institutional capital they sorely need.
- Industry Trends
Rescheduling Stalemate Leaves MSOs Facing a Billion Dollar Tax Reckoning
The Trump administration’s continued inaction on its promise to push ahead with the highly anticipated cannabis rescheduling project is now presenting some real-world issues for many of the sector’s largest players.
- Industry Trends
Is a Cannabis M&A Tidal Wave on the Way?
At the end of the month (March 30, 2026), shareholders of one of the fastest growing Canadian licenced producers, Organigram Global, will convene to decide the fate of its proposed €250m acquisition of Sanity Group.
- Cultivation
Business Brief: Canify and MG Health Announce Merger
German pharmaceutical cannabis company Canify AG and African medical cannabis cultivator MG Health Limited have announced a planned merger, marking yet another M&A deal in a market widely expected to see an incoming wave of consolidation.
- Clinical Research
Rescheduling Will Reprice Medical IP, Not Retail Footprints
US cannabis rescheduling is unlikely to trigger a land grab.
- Industry Trends
The Scramble for Europe
Last month, the German cannabis market saw its most significant consolidation deal to date, as Canadian heavyweight Organigram announced plans to acquire Sanity Group in a deal worth up to €250m.
- M&A Activity
Curaleaf Laboratories and Sanity Group Announce Partnership to Advance Medical Cannabis Innovation in the UK
Curaleaf Laboratories, one of the UK-leading pharmaceutical-grade medical cannabis manufacturers, is delighted to announce a partnership with Berlin-based Sanity Group, a European life science company focused on cannabinoids and wellbeing products.
- Investment & Finance
Business Brief: Safe Harbor Capitalises on Rescheduling Momentum with Financial Ecosystem Offering
Cannabis fintech Safe Harbor Financial is positioning itself to capitalise on the regulatory tailwinds created by federal rescheduling, launching new service partnerships and renegotiating core banking agreements in a bid to fill the severe financial infrastructure gap in the US cannabis industry.
- M&A Activity
Business Brief: Argent Biopharma’s Revenues Drop, Outgoings Rise Ahead of AusCann Deal
Argent Biopharma, formerly MGC Pharmaceuticals, has entered 2026 in a precarious financial position, according to its recently published quarterly figures.
- Industry Trends
AI: The Last Refuge of the Failed Cannabis Company
Late last month, NASDAQ-listed cannabis operator Flora Growth, which once operated one of Colombia’s largest outdoor cultivation facilities, became the latest to exit the cannabis industry, rebranding as an AI-focused digital asset firm ZeroStack Corp.
- Investment & Finance
Rescheduling Optimism Fades, Cannabis Stocks Follow
It is now nearly two months since President Donald Trump surprised the global cannabis industry by signing an executive order to drag the highly-anticipated cannabis rescheduling process out of the bureaucratic swamp.
